Effect of thiazolidinediones on high-density lipoprotein subfractions

Academic Article

Abstract

  • Objective: To evaluate the effects of thiazolidinediones (TZDs) on specific high-density lipoprotein (HDL) subfractions (HDL2 and HDL3) in patients with type 2 diabetes. Methods: We conducted a case-control study in a university diabetes clinic. The study included 45 patients with type 2 diabetes mellitus and dyslipidemia; 31 of these patients received a TZD (troglitazone), and 14 patients received metformin. At the time of the study, the mean duration of therapy was 7 and 11 months, respectively. Results: In the TZD group, a significant increase of 12.6% occurred in the total HDL levels (from 34.9 ± 2.2 mg/dL to 39.3 ± 2.2 mg/dL; P = 0.0008), whereas no significant change was noted in the metformin group (from 40.9 ± 3.5 mg/dL to 40.1 ± 3.2 mg/dL; P = 0.14). All the increase in total HDL levels in the TZD group was due to an increase in the HDL3 subfraction, which rose by 16.7% (from 26.9 ± 0.9 mg/dL to 31.4 ± 1.2 mg/dL; P = 0.008). The HDL2 subfraction remained essentially unchanged (from 8.1 ± 1.7 mg/dL to 7.9 ± 1.4 mg/dL; P = 0.80). In the metformin group, no significant changes were found in either the HDL3 or the HDL2 subfractions. Conclusion: The TZD-induced increase in total HDL levels in our patients was entirely attributable to an increase in the HDL3 subfraction.
  • Authors

    Published In

  • Endocrine Practice  Journal
  • Digital Object Identifier (doi)

    Author List

  • Ovalle F; Bell DSH
  • Start Page

  • 102
  • End Page

  • 104
  • Volume

  • 8
  • Issue

  • 2